Relationship of ADHD Symptoms and Global Illness Severity in Adults Treated with Lisdexamfetamine Dimesylate

References

• . Kessler RC, Adler L, Barkley R, . The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–723
   PubMed Web of Science ®Google Scholar
• . Biederman J, Petty CR, Fried R, . Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J Clin Psychiatry. 2008;69(8):1217–1222
   PubMed Web of Science ®Google Scholar
• . Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67(4):524–540
   PubMed Web of Science ®Google Scholar
• . American Psychiatric Association. Attention-deficit and disruptive behavior disorders. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5). Washington, DC: American Psychiatric Association; 2013:59–65
   Google Scholar
• . Gibbins C, Weiss M. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr Psychiatry Rep. 2007;9:420–426
   PubMedGoogle Scholar
• . Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28(11):1892–1908
   PubMed Web of Science ®Google Scholar
• . Frank E, Prien RF, Jarrett RB, . Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851–855
   PubMed Web of Science ®Google Scholar
• . DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford Press; 1998
   Google Scholar
• . Swanson J. The SNAP-IV Teacher and Parent Rating Scale. http://www.adhd.net/snap-iv-form.pdf. Accessed February 20, 2014
   Google Scholar
• . Durell TM, Adler LA, Williams DW, . Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2013;33(1):45–54
   PubMed Web of Science ®Google Scholar
• . Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS) Technical Manual. New York: Multi-Health Systems; 1999
   Google Scholar
• . Swanson JM, Kraemer HC, Hinshaw SP, . Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40(2):168–179
   PubMed Web of Science ®Google Scholar
• . Stein MA, Sarampote CS, Waldman ID, . A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112(5):e404
   PubMed Web of Science ®Google Scholar
• . Brown TE, Brams M, Gasior M, . Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults. Curr Med Res Opin. 2011;27( Suppl 2):23–33
   PubMed Web of Science ®Google Scholar
• . Biederman J, Petty CR, Fried R, . Stability of executive function deficits into young adult years: a prospective longitudinal follow-up study of grown up males with ADHD. Acta Psychiatr Scand. 2007;116(2):129–136
   PubMed Web of Science ®Google Scholar
• . Brown TE. Executive functions and attention deficit hyperactivity disorder: implications of two conflicting views. Int J Disabilty Develop Educ. 2006;53(1):35–46
   Google Scholar
• . US Department of Health and Human Services. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. http://www.ispor.org/workpaper/FDA%20PRO%20Guidance.pdf. Accessed February 20, 2014
   Google Scholar
• . Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials. 2004;25(6):535–552
   PubMedGoogle Scholar
• . Escobar R, Schacht A, Wehmeier PM, Wagner T. Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials. J Clin Psychopharmacol. 2010;30(2):145–151
   PubMed Web of Science ®Google Scholar
• . Goodman D, Faraone SV, Adler LA, Dirks B, Hamdani M, Weisler R. Interpreting ADHD rating scale scores: linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Prim Psychiatry. 2010;17(3):44–52
   Google Scholar
• . Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration; NIMH Psychopharmacology Research Branch; 1976:218–222
   Google Scholar
• . Atkinson M, Hollis C. NICE guideline: attention deficit hyperactivity disorder. Arch Dis Child Educ Pract Ed. 2010;95(1):24–27
   PubMed Web of Science ®Google Scholar
• . Canadian Attention Deficit Hyperactivity Disorder Resource Alliance. Canadian ADHD Practice Guidelines, 3rd ed. Toronto, ON: Canadian Attention Deficit Hyperactivity Disorder Resource Alliance; 2011
   Google Scholar
• . Biederman J, Mick E, Surman C, . A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59:829–835
   PubMed Web of Science ®Google Scholar
• . Medori R, Ramos-Quiroga JA, Casas M, . A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63:981–989
   PubMed Web of Science ®Google Scholar
• . Spencer TJ, Adler LA, McGough JJ, . Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380–1387
   PubMed Web of Science ®Google Scholar
• . Weisler RH, Biederman J, Spencer TJ, . Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11:625–639
   PubMed Web of Science ®Google Scholar
• . Adler LA, Goodman DW, Kollins SH, . Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–1373
   PubMed Web of Science ®Google Scholar
• . Rosler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin NeuroSci. 2009;259(2):120–129
   PubMed Web of Science ®Google Scholar
• . European Medicines Agency. ICH Topic E10: Choice of Control Group in Clinical Trials. London: European Medicines Agency; 2001
   Google Scholar
• . Evans CHJ Jr, Ildstad ST, eds. Small Clinical Trials: Issues and Challenges. Washington DC: National Academy Press; 2001
   Google Scholar
• . Brams M, Weisler R, Findling RL, . Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73(7):977–983
   PubMed Web of Science ®Google Scholar
• . Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34
   PubMed Web of Science ®Google Scholar
• . Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr. 2009;14(10):573–585
   PubMed Web of Science ®Google Scholar
• . American Psychiatric Association. Attention-deficit and disruptive behavior disorders. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000:85–93
   Google Scholar
• . Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:187–201
   PubMed Web of Science ®Google Scholar
• . Patterson DA, Lee MS. Field trial of the Global Assessment of Functioning Scale—Modified. Am J Psychiatry. 1995;152(9):1386–1388
   PubMed Web of Science ®Google Scholar
• . Buitelaar JK, Wilens TE, Zhang S, Ning Y, Feldman PD. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry. 2009;50(3):335–342
   PubMed Web of Science ®Google Scholar